A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetics of Napabucasin Combined with Sorafenib in Japanese Patients with Unresectable Hepatocellular Carcinoma

Abstract Background and Objective For patients with advanced hepatocellular carcinoma (HCC), the standard of care for many years has been sorafenib. Preliminary data have suggested that the combination of the NAD(P)H:quinone oxidoreductase 1 bioactivatable agent napabucasin plus sorafenib may improv...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Takuji Okusaka (Yazar), Manabu Morimoto (Yazar), Yuichiro Eguchi (Yazar), Shinichiro Nakamura (Yazar), Shuichi Iino (Yazar), Rie Kageyama (Yazar)
Materyal Türü: Kitap
Baskı/Yayın Bilgisi: Adis, Springer Healthcare, 2023-05-01T00:00:00Z.
Konular:
Online Erişim:Connect to this object online.
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Internet

Connect to this object online.

3rd Floor Main Library

Detaylı Erişim Bilgileri 3rd Floor Main Library
Yer Numarası: A1234.567
Kopya Bilgisi 1 Kütüphanede